Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).

They pointed out that reimbursement has already been granted for empagliflozin to treat patients with heart failure and mildly reduced or preserved ejection fraction – above 40% – in other ...

"In its phase 3 trials, empagliflozin has shown a ... three million adults in the US with preserved ejection fraction, a form of heart failure that has very limited treatment options." ...

The EF is normally 50% to 75%, so heart failure with an EF of less than 50% is heart failure with reduced ejection fraction ...

Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.

In 2022, empagliflozin (Jardiance) was approved for a broader indication in heart failure across the spectrum of ejection fraction (EF). In 2023, another SGLT2 inhibitor, dapagliflozin (Farxiga ...